(Q35976379)

11 August 2017

1 reference

title

The search for novel antipsychotics: pharmacological and molecular targets (English)

1 reference

11 August 2017

David J Sanger

1

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 December 2004

1 reference

Expert Opinion on Therapeutic Targets

11 August 2017

published in

1 reference

11 August 2017

volume

8

1 reference

11 August 2017

issue

6

1 reference

11 August 2017

page(s)

631-641

1 reference

The neurodevelopmental hypothesis of schizophrenia: a review of recent developments.

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.6.631

New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.6.631

A meta-analysis of the efficacy of second-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.6.631

Mechanisms of action of atypical antipsychotic drugs: a critical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.6.631

Atypical antipsychotics: are some more atypical than others?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.6.631

Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.6.631

NNC 01-0687, a selective dopamine D1 receptor antagonist, in the treatment of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.6.631

Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.6.631

Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.6.631

Dopamine D3 receptor gene Ser9Gly variant and schizophrenia: association study and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.6.631

Effects of the D3 and autoreceptor-preferring dopamine antagonist (+)-UH232 in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.6.631

Recent advances in the development of dopamine D(3) receptor agonists and antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.6.631

Dopamine D4 receptors elevated in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.6.631

Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.6.631

Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.6.631

Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.6.631

Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine(preclamol) in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.6.631

Partial dopamine agonists in the treatment of psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.6.631

Aripiprazole, a novel atypical antipsychotic drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.6.631

Dopamine partial agonists: a new class of antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.6.631

Aripiprazole (OPC-14597) fully substitutes for the 5-HT1A receptor agonist LY293284 in the drug discrimination assay in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.6.631

Novel antipsychotics in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.6.631

Serotonin receptors: their key role in drugs to treat schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.6.631

Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.6.631

A revised excitotoxic hypothesis of schizophrenia: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.6.631

Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.6.631

Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.6.631

N-methyl-D-aspartate receptor-coupled glycineB receptors in the pathogenesis and treatment of schizophrenia: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.6.631

Discovery and SAR of org 24598-a selective glycine uptake inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.6.631

A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.6.631

Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.6.631

Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.6.631

NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.6.631

A 25 year adventure in the field of tachykinins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.6.631

Muscarinic receptors as a target for drugs treating schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.6.631

N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl- d -aspartate receptor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.6.631

Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.6.631

Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.6.631

Genes for schizophrenia? Recent findings and their pathophysiological implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.6.631

Serotonin-dopamine interaction and its relevance to schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.8.6.631

21 January 2018

Identifiers

DOI

10.1517/14728222.8.6.631

1 reference

11 August 2017

1 reference